Navigation Links
Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference
Date:9/9/2009

CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009, at 1:35 p.m. ET at the Grand Hyatt New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at '/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... TransPack Toon gives users ... can choose from wipes and framing transitions in 30 different styles. Presets range from ... Final Cut Pro X. , TransPack Toon features 90 cartoon transitions from 30 unique ...
(Date:9/3/2015)... York (PRWEB) , ... September 03, 2015 , ... William ... William Mattar, Esq. believes this does not stop at any certain demographic or ... to its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed ...
(Date:9/3/2015)... NH (PRWEB) , ... September 03, 2015 , ... ... new agreement with Amerinet Inc., a leading national healthcare solutions organization, to provide ... Epic EMR. , Through this agreement, Amerinet members will receive negotiated pricing on ...
(Date:9/3/2015)... South Bend, IN (PRWEB) , ... September 03, ... ... Mayo Clinic, Rochester, MN, and Indiana University, Indianapolis, have chosen Center for ... immediately, physicians from these institutions will train at CHC as part of fulfilling ...
(Date:9/3/2015)... ... September 03, 2015 , ... DriButts, a ... partnered with Slingshot® Product Development Group to manufacture a long-lasting reusable diaper for ... with DriButts plans to bring 600 DriButts Diapers to rural areas of Haiti ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3
... , , WASHINGTON , ... (National Council) is offering small emergency grants and free Mental Health ... of the devastating Haiti earthquake. , "Our thoughts are ... ones in the U.S. We commend the efforts of many agencies ...
... that launch glioblastoma multiforme, the most lethal type of brain ... scientists from The University of Texas M. D. Anderson Cancer ... the Jan. 15 issue of Clinical Cancer Research . ... also known as cancer stem cells, stifles the immune response ...
... Long-term use of low-dose versions affect women most, study finds, ... decrease bone density in young women, a new study suggests. ... years, and those on the low-dose estrogen pills appear to ... spine and whole body, according to the researchers. , "I ...
... Irritable bowel syndrome (IBS) is a common gastrointestinal ... well being. Multiple interacting mechanisms, including alterations in ... IBS aetiology. A research article to be ... World Journal of Gastroenterology addresses this question. ...
... increasing worldwide and its prognosis is very poor. ... early detection and on surgical treatment for better ... team from China retrospectively evaluated 5311 liver cancer ... December 2003. Of these, 429 (8.1%) patients were ...
... ... the new year by expanding their existing Green Bay, WI presence with the purchase ... ... technology company representing both businesses and residents has joined forces with Buildmyownsite, Inc., a ...
Cached Medicine News:Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 2Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 3Health News:Cancer stem cells suppress immune response against brain tumor 2Health News:Cancer stem cells suppress immune response against brain tumor 3Health News:The Pill May Decrease Bone Density 2Health News:The Pill May Decrease Bone Density 3Health News:Infinity Technology, Inc. Acquires Build My Own Site, Inc. 2
(Date:9/3/2015)... -- Omeros Corporation (NASDAQ: OMER ) today announced that ... Inc. and its subsidiary, Par Sterile Products, LLC, (collectively ... of New Jersey and in ... Delaware . The lawsuits were filed under ... patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856, which ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hs5hvr/investigation ... "Investigation Report on China Tamsulosin Market, 2010-2019" ... with other a1- adrenergic receptor blockers, tamsulosin hydrochloride ... risk of urinary tract infections and therefore is ... in 1993 in Japan , ...
(Date:9/3/2015)... BALTIMORE , September 3, 2015 ... that its subsidiary Lupin Pharmaceuticals, Inc. (Lupin) has ... which is the first and only generic Duloxetine ... strength. Lupin is excited to bring this new ... currently available dosing options for greater flexibility of ...
Breaking Medicine Technology:Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 3Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: